Please login to the form below
Xalkori
This page shows the latest Xalkori news and features for those working in and with pharma, biotech and healthcare.
Pfizer’s Lorviqua receives EC approval for treatment of advanced lung cancer
The approval is based on the phase 3 CROWN trial comparing Lorviqua with Xalkori. ... The first group received Lorviqua monotherapy and the second group received Xalkori monotherapy.
Latest news
-
Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC
There were 17 patients in the Lorbrena arm and 13 in the Xalkori arm with measurable brain metastases based on baseline imaging. ... In addition, the intracranial duration of response was 12 months or longer in 79% of Lorbrena-treated patients compared
-
FDA sets January decision date for Xalkori in ALK-positive lymphoma
Across both studies, Xalkori demonstrated encouraging anti-tumour activity with Xalkori in children and adults with ALK-positive ALCL. ... Xalkori could represent an important step toward improving outcomes for children with this type of cancer,” he
-
Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
Results showing that the drug is an improvement on Xalkori were released at ESMO 2020 virtual congress. ... In the same trial, the progression-free survival rate was not yet estimable for Lorbrena, compared to 9.3 months for Xalkori.
-
Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer
At the planned interim analysis, Lorbrena came out on top, demonstrating a significantly improved progression-free survival rate compared to Xalkori. ... Currently, Lorbrena is approved only in the second-line setting, for patients who have already been
-
Pfizer’s Talzenna cleared for breast cancer in Europe
Talzenna is one of four new targeted therapies it is hoping will drive growth in cancer, along with Xalkori follow-up Lorbrena (lorlatinib) in second-line ALK-positive NSCLC, SMO inhibitor ... The latest approval is another pillar in its bid to rebuild
More from news
Approximately 25 fully matching, plus 52 partially matching documents found.
Latest Intelligence
-
Pharma deals during November 2014
In addition Merck KGaA also gets the right to co-promote Xalkori in the US and other "key" markets.
-
Oncology drugs under AMNOG: part two
of Xalkori, below - the drug can achieve accelerated approval on the basis of an interim analysis or phase II data before OS is established. ... Outcome. Xalkori(crizotinib) in NSCLC. No OS benefit shown but positive data in morbidity (symptom improvement
-
Who tops the pharma list?
Pfizer's Xalkori is just one example of this.”. Alongside oncology, treatments for immunology and metabolic diseases rank among the fastest-growing therapeutic classifications.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
fox&cat
Fox&cat is a new kind of fully-integrated communications agency – one that delivers genuinely inspirational campaigns and programmes with equal...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
